Health written question – answered at on 14 May 2007.
To ask the Secretary of State for Health what estimate she has made of the financial impact on the NHS of positive National Institute for Health and Clinical Excellence appraisals for medicines for lung cancer.
There is currently no extant completed technology appraisal from the National Institute for Health and Clinical Excellence (NICE) of medicines for lung cancer. However, NICE published an appraisal of docetaxel, paclitaxel, gemcitabine, and vinorelbine for non small-cell lung cancer in June 2001. This appraisal was updated by and incorporated into the clinical guideline on lung cancer published in February 2005. NICE's estimate of full-year costs in England and Wales was £9.55 million.
NICE is currently undertaking two Single Technology Appraisals (STAs) on Tarceva and Alimta for non small-cell lung cancer.
Yes0 people think so
No3 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.